Background and Purpose
The sole FDA approved treatment for stroke is tPA, but its brief therapeutic window and complications of treatment constrain its use. One limitation may be its potential to exacerbate impairment of cerebral autoregulation after stroke. Vasodilation is maintained by elevations in cAMP. However, cAMP levels fall after stroke due to over-activation of NMDA receptors (NMDA-Rs) by toxic levels of glutamate, an effect that is exacerbated by tPA. Binding of wild type (wt-) tPA to the low-density lipoprotein-related receptor (LRP) mediates dilation. We propose that binding of wt-tPA to NMDA-Rs reduces cAMP and impairs vasodilation. We hypothesize that tPA-A296-299, a variant that is fibrinolytic but cannot bind to NMDA-Rs, preferentially binds to LRP and increases cAMP and p38, limiting autoregulation impairment after stroke.
Methods
Stroke was induced by photothrombosis in pigs equipped with a closed cranial window, CBF determined by microspheres, and CSF cAMP and p38 determined by ELISA.
Results
Stroke decreased CBF. CBF was reduced further during hypotension, indicating impairment of autoregulation. Autoregulation was further impaired by wt-tPA, which was prevented by MK801 and tPA-A296-299. Protection by tPA-A296-299 was blocked by anti-LRP Ab, the LRP antagonist RAP, and the p38 inhibitor SB 203580, but not by control IgG. Stroke reduced CSF cAMP, which was reduced further by wt-tPA, but augmented by tPA-A296-299. CSF p38 was unchanged by wt-tPA, increased by tPA-A296-299, and decreased by anti-LRP Ab and RAP.
Conclusions
tPA-A296-299 prevents impairment of cerebral autoregulation after stroke through a LRP-dependent increase in cAMP and p38.